Drug intelligence / Profile preview

CS21095

Development stage: Unknown
Lead developer: Akeso
Modality: PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules

Overview

CS21095 is a small-molecule estrogen receptor (ER) degrader being developed by Chipscreen Biosciences for the treatment of breast cancer. As a targeted protein degrader (TPD), it is designed to bind to the estrogen receptor and induce its degradation via the proteasome pathway, thereby inhibiting the growth of ER-positive breast cancer cells. This mechanism aims to overcome resistance associated with traditional ER antagonists or selective estrogen receptor modulators (SERMs). It is currently in Phase 1 clinical development.

Targets

ER (Estrogen receptor)

Beyond the preview

Go deeper on CS21095.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CS21095.

Explore the full profile